{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:36:17Z","timestamp":1794857777294,"version":"4.9.1"},"reference-count":190,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002806","name":"Carl Zeiss Meditec AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.survophthal.2024.03.009","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T23:02:08Z","timestamp":1711062128000},"page":"521-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review"],"prefix":"10.1016","volume":"69","author":[{"given":"Neil M.","family":"Bressler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bradvica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy Yeeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungkee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clinthera.2011.12.005","article-title":"Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States","volume":"34","author":"Ahmed","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.survophthal.2024.03.009_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.917814","article-title":"Switching among biosimilars: a review of clinical evidence","volume":"13","author":"Allocati","year":"2022","journal-title":"Front Pharm"},{"key":"10.1016\/j.survophthal.2024.03.009_bib3","unstructured":"Alvotech Swiss. Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (ALVOEYE) 2023 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05155293\u3009 (Last accessed February 07, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib4","unstructured":"American Academy of Ophthalmology - Board of Trustees. The Use of Biosimilars in Ophthalmic Practice 2022 [Available from: \u3008https:\/\/www.aao.org\/education\/clinical-statement\/use-of-biosimilars-in-ophthalmic-practice\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib5","unstructured":"American Society of Retina Specialists. 2022 Global Trends in Retina Survey 2022 [Available from: \u3008https:\/\/www.asrs.org\/content\/documents\/2022-asrs-global-trends-in-retina-survey.pdf\u3009 (Last accessed March 20, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib6","unstructured":"Amgen. Amgen Pipeline 2023 [Available from: \u3008https:\/\/www.amgenpipeline.com\/\u3009 (Last accessed May 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib7","unstructured":"Amgen. Amgen reports third quarter financial results 2023 [Available from: \u3008https:\/\/www.amgen.com\/newsroom\/press-releases\/2023\/10\/amgen-reports-third-quarter-financial-results\u3009 (Last accessed February 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib8","unstructured":"Amgen. A. Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea\u00ae) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] 2023 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04270747\u3009 (Last accessed May 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib9","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.2147\/OPTH.S307746","article-title":"Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (wet) age-related macular degeneration","volume":"15","author":"Apsangikar","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104467","article-title":"Biosimilars in rheumatology","volume":"149","author":"Araujo","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.survophthal.2024.03.009_bib11","unstructured":"Association for Accessible Medicines. The U.S. Generic & Biosimilar Medicines Savings Report - September 2022 2022 [Available from: \u3008https:\/\/accessiblemeds.org\/sites\/default\/files\/2022\u201309\/AAM-2022-Generic-Biosimilar-Medicines-Savings-Report.pdf\u3009 (Last accessed March 23, 2023)."},{"issue":"11","key":"10.1016\/j.survophthal.2024.03.009_bib12","article-title":"Oncology biosimilars: New developments and future directions","volume":"5","author":"Bachu","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"10","key":"10.1016\/j.survophthal.2024.03.009_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","article-title":"Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry","volume":"77","author":"Bergstra","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.survophthal.2024.03.009_bib14","unstructured":"Biocon Biologics. Biocon Biologics Receives MHRA, UK Approval for YESAFILI\u00ae, Biosimilar Aflibercept 2023 [Available from: \u3008https:\/\/www.biocon.com\/docs\/BioconBiologics_SE_Notification_Afli_MHRA_Approval_Nov13_2023.pdf\u3009 (Last accessed February 08, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib15","unstructured":"Bioeq. Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea\u00ae in Patients With Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD) 2023 [Available from: \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04522167\u3009 (Last accessed February 07, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib16","unstructured":"BR&R. Biosimilar Approval Status 2024 [Available from: \u3008https:\/\/biosimilarsrr.com\/us-biosimilar-filings\/\u3009 (Last accessed February 09, 2024)."},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","article-title":"Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial","volume":"141","author":"Bressler","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.03.009_bib18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","article-title":"Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes","volume":"107","author":"Bressler","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.03.009_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00417-019-04569-8","article-title":"Off-label use of bevacizumab for wet age-related macular degeneration in Europe","volume":"258","author":"Bro","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"14","key":"10.1016\/j.survophthal.2024.03.009_bib20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2024.03.009_bib21","unstructured":"Cardinal Health. 2023 Biosimilars Report - Tracking market expansion and sustainability amidst a shifting industry 2023 [Available from: \u3008https:\/\/www.cardinalhealth.com\/content\/dam\/corp\/web\/documents\/Report\/cardinal-health-biosimilars-report-2023.pdf\u3009 (Last accessed March 22, 2023)."},{"issue":"20","key":"10.1016\/j.survophthal.2024.03.009_bib22","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2024.03.009_bib23","unstructured":"Celltrion. Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema 2022 [Available from: \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04739306?term=CT-P42&draw=1&rank=1\u3009 (Last accessed May 10, 2023)."},{"issue":"5","key":"10.1016\/j.survophthal.2024.03.009_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","article-title":"Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies","volume":"36","author":"Cohen","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.survophthal.2024.03.009_bib25","unstructured":"Coherus. Coherus to Launch CIMERLI\u2122 (ranibizumab-eqrn) in the United States on October 3, 2022 2022 [Available from: \u3008https:\/\/investors.coherus.com\/news-releases\/news-release-details\/coherus-launch-cimerlitm-ranibizumab-eqrn-united-states-october\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib26","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fphar.2019.01372","article-title":"The clinical implications of nocebo effects for biosimilar therapy","volume":"10","author":"Colloca","year":"2019","journal-title":"Front Pharm"},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib27","first-page":"911","article-title":"Biosimilars in dermatology: the wind of change","volume":"18","author":"Constantin","year":"2019","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ophtha.2017.07.005","article-title":"Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration","volume":"125","author":"Daien","year":"2018","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.survophthal.2024.03.009_bib29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","article-title":"Identifying key benefits in european off-patent biologics and biosimilar markets: it is not only about price!","volume":"34","author":"Dutta","year":"2020","journal-title":"BioDrugs"},{"issue":"13","key":"10.1016\/j.survophthal.2024.03.009_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23136966","article-title":"Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response","volume":"23","author":"Elhag","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.survophthal.2024.03.009_bib32","unstructured":"Endpoint News. Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer 2022 [Available from: \u3008https:\/\/endpts.com\/interchangeability-without-switching-studies-fda-explains-why-a-new-lucentis-biosimilar-may-be-a-game-changer\/\u3009 (Last accessed March 13, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib33","unstructured":"EU Clinical Trials Register. Clinical trials for QL1205 2024 [Available from: \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=QL1205\u3009 (Last accessed February 09, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib34","unstructured":"European Agency for the Evaluation of Medicinal Products. Points to consider on application with 1. meta-analyses; 2. one pivotal study 2001 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/points-consider-application-1meta-analyses-2one-pivotal-study_en.pdf\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib35","unstructured":"European Generic Medicines Association. Biosimilars Handbook 2016 [Available from: \u3008https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/03\/EGA_BIOSIMILARS_handbook_en.pdf\u3009 (Last accessed March 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib36","unstructured":"European Medicines Agency. Authorisation of medicines [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib37","unstructured":"European Medicines Agency. Biosimilar medicines: marketing authorisation [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/biosimilar-medicines-marketing-authorisation\u3009 (Last accessed March 15, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib38","unstructured":"European Medicines Agency. Biosimilar medicines: Overview [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview\u3009 (Last accessed March 14, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib39","unstructured":"European Medicines Agency. Biosimilars in the EU - Information guide for healthcare professionals 2019 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf\u3009 (Last accessed March 3, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib40","unstructured":"European Medicines Agency. Byooviz: EPAR - Medicine overview 2021 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/overview\/byooviz-epar-medicine-overview_en.pdf\u3009 (Last accessed May 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib41","unstructured":"European Medicines Agency. EPAR - Public assessment report - Byooviz 2021 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/byooviz-epar-public-assessment-report_en.pdf\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib42","unstructured":"European Medicines Agency. Generic and hybrid applications [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/generic-medicines\/generic-hybrid-applications\u3009 (Last accessed March 15, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib43","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - Revision 1 2015 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib44","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) 2014 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib45","unstructured":"European Medicines Agency. ICH Topic Q5E: Comparability of Biotechnological\/Biological Products 2005 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-5-e-comparability-biotechnological\/biological-products-step-5_en.pdf\u3009 (Last accessed March 16, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib46","unstructured":"European Medicines Agency. Medicines - Search 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\u3009 (Last accessed March 24, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib47","unstructured":"European Medicines Agency. Onbevzi 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/onbevzi\u3009 (Last accessed March 30, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib48","unstructured":"European Medicines Agency. Rimmyrah - Overview 2024 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rimmyrah#ema-inpage-item-product-info\u3009 (Last accessed February 08, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib49","unstructured":"European Medicines Agency. Ximluci: EPAR - Medicine overview 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ximluci-epar-medicine-overview_en.pdf\u3009 (Last accessed March 17, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib50","unstructured":"European Medicines Agency. Ximluci: EPAR - Public Assessment Report 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ximluci-epar-public-assessment-report_en.pdf\u3009 (Last accessed March 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib51","unstructured":"European Medicines Agency. Yesafili - Overview 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yesafili\u3009 (Last accessed February 08, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib52","unstructured":"European Medicines Agency and Heads of Medicines Agencies. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib53","unstructured":"European Parliament and the Council of the European Union. Directive 2001\/83\/EC of 6 November 2001 on the Community code relating to medicinal products for human use 2022 [Available from: \u3008https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:02001L0083\u201320220101&from=EN\u3009 (Last accessed March 15, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib54","unstructured":"Fatima R., Bittar K., Aziz M. Infliximab 2023 [Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500021\/\u3009 (Last accessed March 23, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib55","unstructured":"Formycon. Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea\u00ae (aflibercept) 2023 [Available from: \u3008https:\/\/www.formycon.com\/en\/blog\/press-release\/ema-submission-fyb203\/\u3009 (Last accessed February 09, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib56","unstructured":"Formycon. Formycon announces file acceptance for FYB203, a biosimilar candidate to Eylea\u00ae (aflibercept), by the U.S. Food and Drug Administration (FDA) 2023 [Available from: \u3008https:\/\/www.formycon.com\/en\/blog\/press-release\/file-acceptance-fyb203\/\u3009 (Last accessed February 08, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib57","unstructured":"Formycon. Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA) 2023 [Available from: \u3008https:\/\/www.formycon.com\/en\/blog\/press-release\/fda-submission-for-fyb203\/\u3009 (Last accessed July 17, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib58","unstructured":"Formycon. FYB201 - Ranibizumab biosimilar candidate [Available from: \u3008https:\/\/www.formycon.com\/en\/biosimilars\/fyb201\/\u3009 (Last accessed February 09, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib59","unstructured":"Generics and Biosimilars Initiative. Advances for STADA-Xbrane\u2019s Ximluci in Europe, the UK and the US 2023 [Available from: \u3008https:\/\/www.gabionline.net\/biosimilars\/news\/advances-for-stada-xbrane-s-ximluci-in-europe-the-uk-and-the-us\u3009 (Last accessed May 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib60","unstructured":"Generics and Biosimilars Initiative. Cost savings from biosimilars in Canada: actual and projected 2020 [Available from: \u3008https:\/\/gabionline.net\/reports\/Cost-savings-from-biosimilars-in-Canada-actual-and-projected\u3009 (Last accessed March 22, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib61","unstructured":"Generics and Biosimilars Initiative. Progress for Lucentis (ranibizumab) biosimilars in Europe and the US 2022 [Available from: \u3008https:\/\/www.gabionline.net\/biosimilars\/news\/progress-for-lucentis-ranibizumab-biosimilars-in-europe-and-the-us\u3009 (Last accessed May 12, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib62","unstructured":"Genus Pharmaceuticals. Ximluci 10 mg\/mL solution for injection - Summary of Product Characteristics (UK) 2023 [Available from: \u3008https:\/\/www.medicines.org.uk\/emc\/product\/14461\/smpc\/print\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib63","unstructured":"Gerriets V., Kasi A. Bevacizumab 2022 [Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482126\/\u3009 (Last accessed March 30, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib64","unstructured":"Globe Newswire. Anti-VEGF Market Size is projected to reach USD 13.54 Billion by 2030, growing at a CAGR of 1.02%: Straits Research 2022 [Available from: \u3008https:\/\/www.globenewswire.com\/news-release\/2022\/07\/21\/2484044\/0\/en\/Anti-VEGF-Market-Size-is-projected-to-reach-USD-13\u201354-Billion-by-2030-growing-at-a-CAGR-of-1\u201302-Straits-Research.html\u3009 (Last accessed March 27, 2023)."},{"issue":"21","key":"10.1016\/j.survophthal.2024.03.009_bib65","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1001\/jama.2017.5202","article-title":"Obstacles to the adoption of biosimilars for chronic diseases","volume":"317","author":"Hakim","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.survophthal.2024.03.009_bib66","unstructured":"Hanif N., Anwer F. Rituximab 2022 [Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564374\/\u3009 (Last accessed March 23, 2023)."},{"issue":"3","key":"10.1016\/j.survophthal.2024.03.009_bib67","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","article-title":"An introduction to biosimilars for the treatment of retinal diseases: a narrative review","volume":"11","author":"Hariprasad","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001205","article-title":"Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment","volume":"8","author":"Hatamnejad","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"issue":"10326","key":"10.1016\/j.survophthal.2024.03.009_bib69","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40259-020-00463-6","article-title":"Biosimilar perceptions among healthcare professionals and commercial medical benefit policy analysis in the United States","volume":"35","author":"Herndon","year":"2021","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.survophthal.2024.03.009_bib71","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from luminous, a global real-world study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"issue":"38","key":"10.1016\/j.survophthal.2024.03.009_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25380","article-title":"Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT","volume":"25","author":"Hykin","year":"2021","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.survophthal.2024.03.009_bib74","unstructured":"Intas Pharmaceuticals. About RAZUMAB 2023 [Available from: \u3008http:\/\/razumab.co.in\/about.php\u3009 (Last accessed July 14, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib75","unstructured":"Intas Pharmaceuticals. Prescribing Information Ranibizumab (Razumab) 2020 [Available from: \u3008http:\/\/razumab.co.in\/about.php\u3009 (Last accessed July 18, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib76","unstructured":"IQVIA. The Impact of Biosimilar Competition in Europe 2021 [Available from: \u3008https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2021.pdf\u3009 (Last accessed March 14, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib77","unstructured":"IQVIA. The Impact of Biosimilar Competition in Europe 2022 [Available from: \u3008https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2022.pdf\u3009 (Last accessed May 05, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib78","unstructured":"IQVIA Institute for Human Data Science. Biosimilars in the United States 2023\u20132027 - Competition, Savings, and Sustainability 2023 [Available from: \u3008https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/biosimilars-in-the-united-states-2023\u20132027\/iqvia-institute-biosimilars-in-the-united-states-2023-usl-orb3393.pdf\u3009 (Last accessed."},{"issue":"4","key":"10.1016\/j.survophthal.2024.03.009_bib79","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ceo.13706","article-title":"Impact of out-of-pocket costs on patient initiation, adherence and persistence rates for patients treated with anti-vascular endothelial growth factor medicines","volume":"48","author":"Jackson","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib80","unstructured":"Janssen Biologics B.V. Remicade SmPC 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf\u3009 (Last accessed May 11, 2023)."},{"issue":"12","key":"10.1016\/j.survophthal.2024.03.009_bib81","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2024.03.009_bib82","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/JEP.S259298","article-title":"Current and future anti-vegf agents for neovascular age-related macular degeneration","volume":"13","author":"Kaiser","year":"2021","journal-title":"J Exp Pharm"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib83","doi-asserted-by":"crossref","first-page":"1345580","DOI":"10.1080\/20016689.2017.1345580","article-title":"Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region","volume":"5","author":"Kalo","year":"2017","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40942-021-00343-3","article-title":"Future of anti-VEGF: biosimilars and biobetters","volume":"8","author":"Kapur","year":"2022","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.survophthal.2024.03.009_bib85","unstructured":"Kidswell Bio Corporation. 2023 [Available from: \u3008https:\/\/www.kidswellbio.com\/Portals\/0\/resources\/pdf\/en\/20230927\u201302.pdf\u3009 (Last accessed February 08, 2024)."},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib86","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40123-022-00453-7","article-title":"Evaluation of the structural, physicochemical, and biological characteristics of SB11, as Lucentis((R)) (Ranibizumab) Biosimilar","volume":"11","author":"Kim","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"10.1016\/j.survophthal.2024.03.009_bib87","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1002\/bit.26438","article-title":"Biosimilars: Key regulatory considerations and similarity assessment tools","volume":"114","author":"Kirchhoff","year":"2017","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"10.1016\/j.survophthal.2024.03.009_bib88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4161\/mabs.3.3.15474","article-title":"Regulatory pathways in the European Union","volume":"3","author":"Kohler","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.survophthal.2024.03.009_bib89","unstructured":"Korea Biomedical Review. Alteogen begins phase 3 study of Eylea biosimilar to get approval by 2025 2023 [Available from: \u3008https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=20499\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib90","unstructured":"Korea Biomedical Review. Celltrion seeks U.S. marketing authorization for Eylea biosimilar 2023 [Available from: \u3008https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=21476\u3009 (Last accessed July 17, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib91","unstructured":"Korea Biomedical Review. Celltrion\u2019s Eylea biosimilar waits for EMA permission 2023 [Available from: \u3008https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=22611\u3009 (Last accessed February 09, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib92","unstructured":"Korea Biomedical Review. Traditional Korean drugmakers advance into biosimilar market 2023 [Available from: \u3008https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=20339\u3009 (Last accessed May 09, 2023)."},{"issue":"41","key":"10.1016\/j.survophthal.2024.03.009_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/EDBK_100028","article-title":"An arm and a leg: the rising cost of cancer drugs and impact on access","author":"Leighl","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0020731420979824","article-title":"Regulators, pivotal clinical trials, and drug regulation in the age of COVID-19","volume":"51","author":"Lexchin","year":"2021","journal-title":"Int J Health Serv"},{"key":"10.1016\/j.survophthal.2024.03.009_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2023.05.005","article-title":"Randomized trial of biosimilar XSB-001 versus reference ranibizumab in patients with neovascular age-related macular degeneration","author":"Loewenstein","year":"2023","journal-title":"Ophthalmol Retin"},{"issue":"3","key":"10.1016\/j.survophthal.2024.03.009_bib96","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","article-title":"Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community","volume":"31","author":"Markus","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.survophthal.2024.03.009_bib97","unstructured":"Midas Pharma GmbH. Ongavia SmPC 2022 [Available from: \u3008https:\/\/www.medicines.org.uk\/emc\/product\/13885\/smpc\/print\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib98","unstructured":"Midas Pharma GmbH. Ranivisio SmPC 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ranivisio-epar-product-information_en.pdf\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib100","unstructured":"Ministry of Food and Drug Safety of the Republic of Korea. Amelivu [Available from: \u3008https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=202202008aupdateTs2023\u201302-15%2015:44:12.247591b\u3009 (Last accessed March 09, 2023)."},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502747","article-title":"Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset","volume":"243","author":"Mones","year":"2020","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00417-012-2038-0","article-title":"Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration","volume":"251","author":"Muether","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2024.03.009_bib103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.37765\/ajmc.2022.88809","article-title":"Projected US savings from biosimilars, 2021-2025","volume":"28","author":"Mulcahy","year":"2022","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.survophthal.2024.03.009_bib104","unstructured":"Mylan Pharmaceuticals Inc. Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea\u00ae in Subjects With Diabetic Macular Edema (DME) (DME) 2023 [Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03610646?intr=MYL-1701P&rank=1\u3009 (Last accessed August 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib105","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.2147\/DDDT.S378813","article-title":"Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars","volume":"16","author":"Niazi","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.survophthal.2024.03.009_bib106","unstructured":"Novartis Europharm Limited. Lucentis: EPAR - Product Information 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lucentis-epar-product-information_en.pdf\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib107","unstructured":"Outlook Therapeutics. ONS-5010, an Investigational Ophthalmic Formulation of Bevacizumab-vikg \u2013 Clinical Progress 2023 [Available from: \u3008https:\/\/outlooktherapeutics.com\/lytenava-clinical-progress\/\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib108","unstructured":"Outlook Therapeutics. Outlook Therapeutics\u00ae Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD 2022 [Available from: \u3008https:\/\/ir.outlooktherapeutics.com\/news-releases\/news-release-details\/outlook-therapeuticsr-announces-validation-marketing\u3009 (Last accessed May 10, 2023)."},{"issue":"4","key":"10.1016\/j.survophthal.2024.03.009_bib109","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40259-022-00538-6","article-title":"Interchangeability for biologics is a legal distinction in the USA, not a clinical one","volume":"36","author":"Park","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.survophthal.2024.03.009_bib110","unstructured":"Pearce I.P. STADA and Xbrane announce NHS supply of Ximluci\u00ae (ranibizumab), a biosimilar to Roche\/Genentech\u2019s Lucentis\u00ae 2023 [Available from: \u3008https:\/\/www.pearceip.law\/2023\/04\/25\/stada-and-xbrane-announce-nhs-supply-of-ximluci-ranibizumab-a-biosimilar-to-roche-genentechs-lucentis\/\u3009 (Last accessed May 10, 2023)."},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib111","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","article-title":"Patient perspectives on biosimilars: a survey by the european federation of crohn's and ulcerative colitis associations","volume":"11","author":"Peyrin-Biroulet","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.survophthal.2024.03.009_bib112","unstructured":"Pfizer Europe MA EEIG. Inflectra SmPC 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inflectra-epar-product-information_en.pdf\u3009 (Last accessed May 11, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib113","unstructured":"Pfizer Europe MA EEIG. Zirabev SmPC 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zirabev-epar-product-information_en.pdf\u3009 (Last accessed May 11, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib114","unstructured":"Pharma Japan. Lucentis Biosimilar Now Approved for Diabetic Macular Edema 2023 [Available from: \u3008https:\/\/pj.jiho.jp\/article\/248138\u3009 (Last accessed July 14, 2023)."},{"issue":"15_suppl","key":"10.1016\/j.survophthal.2024.03.009_bib115","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2020.38.15_suppl.578","article-title":"Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting","volume":"38","author":"Pivot","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib116","unstructured":"Qilu Pharma Spain. EU Risk Management Plan for Rimmyrah 10 mg\/mL solution for injection 2024 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/rimmyrah-epar-risk-management-plan_en.pdf\u3009 (Last accessed February 08, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib117","unstructured":"Qilu Pharma Spain. Rimmyrah EU SmPC 2024 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rimmyrah-epar-product-information_en.pdf\u3009 (Last accessed February 08, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib118","unstructured":"Qilu Pharmaceutical. Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis\u00ae in Patients With Wet AMD 2019 [Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03312283?intr=QL1205&rank=1\u3009 (Last accessed February 09, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib119","series-title":"Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists, Physicians and Other Health Practitioners","article-title":"Innovator biologics, biosimilars, and biobetters - terminology, nomenclature, and definitions","author":"Ramzan","year":"2020"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40123-021-00416-4","article-title":"Comparison between ranibizumab biosimilar, innovator ranibizumab and bevacizumab in a real-world situation","volume":"11","author":"Ratra","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"10.1016\/j.survophthal.2024.03.009_bib121","doi-asserted-by":"crossref","first-page":"857","DOI":"10.5301\/ejo.5000299","article-title":"Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration","volume":"23","author":"Real","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib122","unstructured":"Reliance Life Sciences. RanizuRel\u2122 2023 [Available from: \u3008https:\/\/www.rellife.com\/web\/lifesciences\/ranizurel\u3009 (Last accessed July 14, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib123","unstructured":"Repository of Korea's Corporate Filings (DART). Quarterly report [Available from: \u3008https:\/\/dart.fss.or.kr\/dsaf001\/main.do?rcpNo=20230515002061\u3009 (Last accessed August 07, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib124","unstructured":"Retina Specialist. With Byooviz, Biogen takes a leap on pricing first U.S. retina biosimilar 2022 [Available from: \u3008https:\/\/www.retina-specialist.com\/article\/with-byooviz-biogen-takes-a-leap-on-pricing-first-us-retina-biosimilar\u3009 (Last accessed May 05, 2023)."},{"issue":"4","key":"10.1016\/j.survophthal.2024.03.009_bib125","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/imj.14787","article-title":"Biologic therapy for uveitis: addressing access issues is paramount","volume":"50","author":"Robinson","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.survophthal.2024.03.009_bib126","unstructured":"Roche Registration GmbH. Avastin SmPC 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avastin-epar-product-information_en.pdf\u3009 (Last accessed May 11, 2023)."},{"issue":"14","key":"10.1016\/j.survophthal.2024.03.009_bib127","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2024.03.009_bib128","unstructured":"Sam Chun Dang Pharm. A Study to Comparing SCD411 and Eylea\u00ae in Subjects With Wet Age-related Macular Degeneration (AMD) 2022 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04480463\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib129","unstructured":"Samsung Bioepis. A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) 2024 [Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04450329?intr=SB15&rank=1\u3009 (Last accessed February 09, 2024)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib130","unstructured":"Samsung Bioepis NL B.V. Aybintio SmPC 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aybintio-epar-product-information_en.pdf\u3009 (Last accessed March 31, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib131","unstructured":"Samsung Bioepis NL B.V. Byooviz: EPAR - Product Information 2023 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byooviz-epar-product-information_en.pdf\u3009 (Last accessed May 11, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib132","unstructured":"Samsung Bioepis NL B.V. Flixabi SmPC 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/flixabi-epar-product-information_en.pdf\u3009 (Last accessed May 11, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib133","unstructured":"Samsung Bioepis UK Limited. Byooviz (UK) SPC 2022 [Available from: \u3008https:\/\/www.medicines.org.uk\/emc\/product\/14606\/smpc\/print\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib134","unstructured":"Sandoz. Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea\u00ae in Patients With Neovascular Age-related Macular Degeneration (Mylight) 2023 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04864834\u3009 (Last accessed February 07, 2024)."},{"issue":"5","key":"10.1016\/j.survophthal.2024.03.009_bib135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034183","article-title":"Physicians' perceptions of the uptake of biosimilars: a systematic review","volume":"10","author":"Sarnola","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.survophthal.2024.03.009_bib136","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiestl","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib137","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2147\/DDDT.S130318","article-title":"Ten years of biosimilars in Europe: development and evolution of the regulatory pathways","volume":"11","author":"Schiestl","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.survophthal.2024.03.009_bib138","unstructured":"Senju Pharmaceutical. Launch of a New Treatment for \u201cRanibizumab BS Intravitreal Injection Kit 10 mg\/mL \"Senju\" 2021 [Available from: \u3008https:\/\/www.senju.co.jp\/sites\/default\/files\/content_news\/2021\u201312\/English_20211209_1.pdf\u3009 (Last accessed March 17, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib139","unstructured":"Shanghai Henlius Biotech. Clinical-stage Products 2023 [Available from: \u3008https:\/\/www.henlius.com\/en\/Product.html\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib140","unstructured":"Shanghai Henlius Biotech. Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD 2023 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05003245?term=hlx04-O&draw=2&rank=3\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib141","unstructured":"Shanghai Henlius Biotech. A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD 2023 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04740671?term=HLX04-O&draw=2&rank=2\u3009 (Last accessed May 10, 2023)."},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib142","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41433-022-02246-5","article-title":"Approved biosimilar ranibizumab-a global update","volume":"37","author":"Sharma","year":"2023","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib143","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bjophthalmol-2019-314443","article-title":"Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective","volume":"104","author":"Sharma","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib144","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","article-title":"Biosimilars for retinal diseases: an update","volume":"224","author":"Sharma","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.03.009_bib145","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41433-021-01616-9","article-title":"Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.survophthal.2024.03.009_bib146","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/24741264231202080","article-title":"Biosimilar to biosimilar anti-vegf switching for retinal diseases","volume":"7","author":"Sharma","year":"2023","journal-title":"J Vitreoretin Dis"},{"issue":"6","key":"10.1016\/j.survophthal.2024.03.009_bib147","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17469899.2022.2152005","article-title":"Emerging biosimilars for retinal diseases","volume":"17","author":"Sharma","year":"2022","journal-title":"Expert Rev Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2024.03.009_bib148","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.4103\/ijo.IJO_2118_21","article-title":"A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis((R)) in patients with neovascular age-related macular degeneration","volume":"70","author":"Singh","year":"2022","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib149","first-page":"54","volume":"44","author":"Smeeding","year":"2019","journal-title":"Biosimilars: Consid Payers P T"},{"issue":"3","key":"10.1016\/j.survophthal.2024.03.009_bib150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ajhp\/zxaa376","article-title":"Biosimilar formulary placement in medicare part d prescription drug plans: a case study of infliximab","volume":"78","author":"Socal","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.survophthal.2024.03.009_bib151","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40123-022-00507-w","article-title":"Innovator versus biosimilar ranibizumab in polypoidal choroidal vasculopathy: real-world evidence","volume":"11","author":"Soman","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.survophthal.2024.03.009_bib152","unstructured":"Stada Arzneimittel AG. STADA and Xbrane launch ranibizumab to support patient access in Europe 2023 [Available from: \u3008https:\/\/www.stada.com\/blog\/posts\/2023\/april\/stada-and-xbrane-launch-ranibizumab-to-support-patient-access-in-europe\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib153","unstructured":"Stada Arzneimittel AG. STADA and Xbrane secure EU approval for Ximluci\u00ae (ranibizumab) biosimilar referencing Lucentis\u00ae 2022 [Available from: \u3008https:\/\/www.stada.com\/blog\/posts\/2022\/november\/stada-and-xbrane-secure-eu-approval-for-ximluci-ranibizumab-biosimilar-referencing-lucentis\u3009 (Last accessed March 17, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib154","unstructured":"Stada Arzneimittel AG. Ximluci SmPC 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ximluci-epar-product-information_en.pdf\u3009 (Last accessed May 11, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib155","unstructured":"The Pharma Letter. 2015 [Available from: \u3008https:\/\/www.thepharmaletter.com\/article\/intas-becomes-first-company-to-launch-biosimilar-of-lucentis\u3009 (Last accessed July 18, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib156","unstructured":"The Pharma Letter. Biogen and Samsung Bioepis\u2019 Byooviz launches in USA 2022 [Available from: \u3008https:\/\/www.thepharmaletter.com\/article\/biogen-and-samsung-bioepis-byooviz-launches-in-usa\u3009 (Last accessed March 09, 2023)."},{"issue":"5","key":"10.1016\/j.survophthal.2024.03.009_bib157","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/btpr.2066","article-title":"Biosimilars advancements: moving on to the future","volume":"31","author":"Tsuruta","year":"2015","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.survophthal.2024.03.009_bib158","unstructured":"U.S. Centers for Medicare & Medicaid Services. Frequently Asked Questions - Inflation Reduction Act - Biosimilars Temporary Payment Increase [Available from: \u3008https:\/\/www.cms.gov\/files\/document\/biosimilar-faqs.pdf\u3009 (Last accessed August 07, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib160","unstructured":"United States Code. 21 U.S.C. 355 - New drugs 2010 [Available from: \u3008https:\/\/www.govinfo.gov\/content\/pkg\/USCODE-2010-title21\/pdf\/USCODE-2010-title21-chap9-subchapV-partA-sec355.pdf\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib161","unstructured":"United States Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book 2023 [Available from: \u3008https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib162","unstructured":"United States Food and Drug Administration. Background Information: List of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations (Purple Book) 2020 [Available from: \u3008https:\/\/www.fda.gov\/drugs\/biosimilars\/background-information-list-licensed-biological-products-reference-product-exclusivity-and\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib163","unstructured":"United States Food and Drug Administration. Biosimilars Info Sheet 4 - Biosimilar Regulatory Approval Pathway [Available from: \u3008https:\/\/www.fda.gov\/media\/154914\/download\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib164","unstructured":"United States Food and Drug Administration. Biosimilars Review and Approval 2022 [Available from: \u3008https:\/\/www.fda.gov\/drugs\/biosimilars\/review-and-approval\u3009 (Last accessed March 3, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib165","unstructured":"United States Food and Drug Administration. Considerations in Demonstrating Interchangeability With a Reference Product - Guidance for Industry 2019 [Available from: \u3008https:\/\/www.fda.gov\/media\/124907\/download\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib166","unstructured":"United States Food and Drug Administration. Exclusivity and Generic Drugs: What Does It Mean? 2020 [Available from: \u3008https:\/\/www.fda.gov\/media\/111069\/download\u3009 (Last accessed May 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib167","unstructured":"United States Food and Drug Administration. FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions 2021 [Available from: \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib168","unstructured":"United States Food and Drug Administration. Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act - Guidance for Industry (Draft Guidance) - Revision 1 2021 [Available from: \u3008https:\/\/www.fda.gov\/media\/97353\/download\u3009 (Last accessed May 10, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib169","unstructured":"United States Food and Drug Administration. Interchangeable Biological Products [Available from: \u3008https:\/\/www.fda.gov\/media\/151094\/download\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib170","unstructured":"United States Food and Drug Administration. Overview of the Regulatory Framework and FDA\u2019s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US 2018 [Available from: \u3008https:\/\/www.fda.gov\/media\/113820\/download\u3009 (Last accessed May 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib171","unstructured":"United States Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product - Guidance for Industry 2015 [Available from: \u3008https:\/\/www.fda.gov\/media\/135612\/download\u3009 (Last accessed March 09, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib172","unstructured":"United States Food and Drug Administration. Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act - Guidance for Industry 2014 [Available from: \u3008https:\/\/www.fda.gov\/media\/89049\/download\u3009 (Last accessed May 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib173","unstructured":"United States Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product - Guidance for Industry 2015 [Available from: \u3008https:\/\/www.fda.gov\/media\/82647\/download\u3009 (Last accessed March 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib174","unstructured":"United States Food and Drug Administration. Text of Compounding Quality Act 2018 [Available from: \u3008https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/text-compounding-quality-act\u3009 (Last accessed August 08, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib175","unstructured":"United States Food and Drug Administration. What Is the Approval Process for Generic Drugs? 2017 [Available from: \u3008https:\/\/www.fda.gov\/drugs\/generic-drugs\/what-approval-process-generic-drugs\u3009 (Last accessed March 08, 2023)."},{"issue":"5","key":"10.1016\/j.survophthal.2024.03.009_bib176","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaci.2017.03.012","article-title":"Biologics in patients with skin diseases","volume":"139","author":"Veilleux","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib177","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijo.IJO_2516_20","article-title":"Clinical efficacy and safety of Razumab(R) (CESAR) study: our experience with the world's first biosimilar Ranibizumab","volume":"69","author":"Verma","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib178","unstructured":"Viatris Inc. (Mylan Pharmaceuticals Inc.). Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea\u00ae in Subjects With Diabetic Macular Edema (DME) 2023 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03610646?term=MYL1701P&draw=2&rank=1\u3009 (Last accessed March 10, 2023)."},{"issue":"suppl_4","key":"10.1016\/j.survophthal.2024.03.009_bib179","doi-asserted-by":"crossref","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","article-title":"The process defines the product: what really matters in biosimilar design and production?","volume":"56","author":"Vulto","year":"2017","journal-title":"Rheumatol (Oxf)"},{"issue":"4","key":"10.1016\/j.survophthal.2024.03.009_bib180","first-page":"353","article-title":"On the regulatory approval pathway of biosimilar products","volume":"5","author":"Wang","year":"2012","journal-title":"Pharm (Basel)"},{"issue":"6","key":"10.1016\/j.survophthal.2024.03.009_bib181","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2024.03.009_bib182","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib183","article-title":"Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial","volume":"8","author":"Woo","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib184","unstructured":"Woo S.J., Sadda S.R., Bradvica M., et al. PO381: SB15, a Proposed Biosimilar to Aflibercept, in nAMD: 32-Week Results. AAO 2022 - American Academy of Ophthalmology Annual Meeting; Chicago, IL, USA2022."},{"issue":"1","key":"10.1016\/j.survophthal.2024.03.009_bib185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.03.009_bib186","unstructured":"World Health Organization. Guidelines on evaluation of Biosimilars, TRS 1043, Annex 3 2022 [Available from: \u3008https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-evaluation-of-biosimilars--trs-1043--annex-3\u3009 (Last accessed March 3, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib187","unstructured":"Xbrane Biopharma. STADA and Xbrane obtain British approval for Ximluci\u00ae (ranibizumab) biosimilar referencing Lucentis\u00ae 2023 [Available from: \u3008https:\/\/xbrane.com\/en\/mfn_news\/stada-and-xbrane-obtain-british-approval-for-ximluci-ranibizumab-biosimilar-referencing-lucentis\/\u3009 (Last accessed March 17, 2023)."},{"key":"10.1016\/j.survophthal.2024.03.009_bib188","unstructured":"Xbrane Biopharma. Xbrane submits BLA for ranibizumab biosimilar candidate to FDA 2023 [Available from: \u3008https:\/\/xbrane.com\/en\/mfn_news\/xbrane-submits-bla-for-ranibizumab-biosimilar-candidate-to-fda\/\u3009 (Last accessed February 09, 2024)."},{"issue":"4","key":"10.1016\/j.survophthal.2024.03.009_bib189","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","article-title":"Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan","volume":"12","author":"Yanagi","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"10.1016\/j.survophthal.2024.03.009_bib190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275611","article-title":"Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial","volume":"17","author":"Yoon","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.survophthal.2024.03.009_bib191","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.18240\/ijo.2022.09.20","article-title":"Efficacy and safety of intravitreal HLX04-O, an anti-VEGF monoclonal antibody, for the treatment of wet age-related macular degeneration","volume":"15","author":"Zhang","year":"2022","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.03.009_bib192","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2014.06.020","article-title":"Targeted biopharmaceuticals for cancer treatment","volume":"352","author":"Zhou","year":"2014","journal-title":"Cancer Lett"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:16:46Z","timestamp":1731619006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625724000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":190,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0039625724000298"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.03.009","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}